A review of rapid-onset opioids for breakthrough pain in patients with cancer

Steven M. Simon, Lee Schwartzberg

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

Pain management in patients with cancer remains suboptimal. Breakthrough pain (BTP) is characterized by abrupt onset of severe pain in a background of otherwise stable managed pain and presents a substantial burden to patients, as it disrupts activities and quality of life. Rapid-onset opioids (ROOs), with an appropriate onset and duration of effect, provide new options for effective and well-tolerated management of BTP. All currently available ROOs are various formulations of transmucosal immediate-release fentanyl (TIRF) and, although they were originally developed and approved for use in children before painful procedures, are only approved for use in opioid-tolerant adult patients with cancer and BTP. The formulation options include oral lozenge, buccal tablet, buccal film, sublingual tablet, nasal spray, and a sublingual spray; each has practical considerations that vary with the product and route of administration. All have the common advantage of rapid entry into the systemic circulation via transmucosal absorption, avoiding hepatic and intestinal first-pass metabolism and allowing a rapid onset of action that rivals intravenous injections. Rapid onset and short duration of action allow good patient control of analgesia. The pharmacokinetic and analgesic properties of ROOs may allow reduction of the total opioid burden and associated adverse effects, while still providing effective pain relief. The shared TIRF risk evaluation and mitigation strategy program implemented in March 2012 has simplified enrollment and administration of these products to help mitigate the risks of abuse and misuse and to help ensure safe use in patients with cancer suffering from BTP.

Original languageEnglish (US)
Pages (from-to)207-215
Number of pages9
JournalJournal of Opioid Management
Volume10
Issue number3
DOIs
StatePublished - Jan 1 2014

Fingerprint

Breakthrough Pain
Opioid Analgesics
Cheek
Fentanyl
Neoplasms
Pain
Tablets
Nasal Sprays
Pain Management
Motion Pictures
Intravenous Injections
Analgesia
Analgesics
Pharmacokinetics
Quality of Life
Liver

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Anesthesiology and Pain Medicine

Cite this

A review of rapid-onset opioids for breakthrough pain in patients with cancer. / Simon, Steven M.; Schwartzberg, Lee.

In: Journal of Opioid Management, Vol. 10, No. 3, 01.01.2014, p. 207-215.

Research output: Contribution to journalReview article

@article{470dfa62040a4dddabf53f511f1d6f61,
title = "A review of rapid-onset opioids for breakthrough pain in patients with cancer",
abstract = "Pain management in patients with cancer remains suboptimal. Breakthrough pain (BTP) is characterized by abrupt onset of severe pain in a background of otherwise stable managed pain and presents a substantial burden to patients, as it disrupts activities and quality of life. Rapid-onset opioids (ROOs), with an appropriate onset and duration of effect, provide new options for effective and well-tolerated management of BTP. All currently available ROOs are various formulations of transmucosal immediate-release fentanyl (TIRF) and, although they were originally developed and approved for use in children before painful procedures, are only approved for use in opioid-tolerant adult patients with cancer and BTP. The formulation options include oral lozenge, buccal tablet, buccal film, sublingual tablet, nasal spray, and a sublingual spray; each has practical considerations that vary with the product and route of administration. All have the common advantage of rapid entry into the systemic circulation via transmucosal absorption, avoiding hepatic and intestinal first-pass metabolism and allowing a rapid onset of action that rivals intravenous injections. Rapid onset and short duration of action allow good patient control of analgesia. The pharmacokinetic and analgesic properties of ROOs may allow reduction of the total opioid burden and associated adverse effects, while still providing effective pain relief. The shared TIRF risk evaluation and mitigation strategy program implemented in March 2012 has simplified enrollment and administration of these products to help mitigate the risks of abuse and misuse and to help ensure safe use in patients with cancer suffering from BTP.",
author = "Simon, {Steven M.} and Lee Schwartzberg",
year = "2014",
month = "1",
day = "1",
doi = "10.5055/jom.2014.0209",
language = "English (US)",
volume = "10",
pages = "207--215",
journal = "Journal of Opioid Management",
issn = "1551-7489",
publisher = "Weston Medical Publishing",
number = "3",

}

TY - JOUR

T1 - A review of rapid-onset opioids for breakthrough pain in patients with cancer

AU - Simon, Steven M.

AU - Schwartzberg, Lee

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Pain management in patients with cancer remains suboptimal. Breakthrough pain (BTP) is characterized by abrupt onset of severe pain in a background of otherwise stable managed pain and presents a substantial burden to patients, as it disrupts activities and quality of life. Rapid-onset opioids (ROOs), with an appropriate onset and duration of effect, provide new options for effective and well-tolerated management of BTP. All currently available ROOs are various formulations of transmucosal immediate-release fentanyl (TIRF) and, although they were originally developed and approved for use in children before painful procedures, are only approved for use in opioid-tolerant adult patients with cancer and BTP. The formulation options include oral lozenge, buccal tablet, buccal film, sublingual tablet, nasal spray, and a sublingual spray; each has practical considerations that vary with the product and route of administration. All have the common advantage of rapid entry into the systemic circulation via transmucosal absorption, avoiding hepatic and intestinal first-pass metabolism and allowing a rapid onset of action that rivals intravenous injections. Rapid onset and short duration of action allow good patient control of analgesia. The pharmacokinetic and analgesic properties of ROOs may allow reduction of the total opioid burden and associated adverse effects, while still providing effective pain relief. The shared TIRF risk evaluation and mitigation strategy program implemented in March 2012 has simplified enrollment and administration of these products to help mitigate the risks of abuse and misuse and to help ensure safe use in patients with cancer suffering from BTP.

AB - Pain management in patients with cancer remains suboptimal. Breakthrough pain (BTP) is characterized by abrupt onset of severe pain in a background of otherwise stable managed pain and presents a substantial burden to patients, as it disrupts activities and quality of life. Rapid-onset opioids (ROOs), with an appropriate onset and duration of effect, provide new options for effective and well-tolerated management of BTP. All currently available ROOs are various formulations of transmucosal immediate-release fentanyl (TIRF) and, although they were originally developed and approved for use in children before painful procedures, are only approved for use in opioid-tolerant adult patients with cancer and BTP. The formulation options include oral lozenge, buccal tablet, buccal film, sublingual tablet, nasal spray, and a sublingual spray; each has practical considerations that vary with the product and route of administration. All have the common advantage of rapid entry into the systemic circulation via transmucosal absorption, avoiding hepatic and intestinal first-pass metabolism and allowing a rapid onset of action that rivals intravenous injections. Rapid onset and short duration of action allow good patient control of analgesia. The pharmacokinetic and analgesic properties of ROOs may allow reduction of the total opioid burden and associated adverse effects, while still providing effective pain relief. The shared TIRF risk evaluation and mitigation strategy program implemented in March 2012 has simplified enrollment and administration of these products to help mitigate the risks of abuse and misuse and to help ensure safe use in patients with cancer suffering from BTP.

UR - http://www.scopus.com/inward/record.url?scp=84904472513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904472513&partnerID=8YFLogxK

U2 - 10.5055/jom.2014.0209

DO - 10.5055/jom.2014.0209

M3 - Review article

VL - 10

SP - 207

EP - 215

JO - Journal of Opioid Management

JF - Journal of Opioid Management

SN - 1551-7489

IS - 3

ER -